Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison

Kennelly, Michael; Rhodes, Thomas; Girman, Cynthia J.; Thomas, Elizabeth; Shortino, Denise; Mudd, Paul N.

doi:10.1007/s12325-021-01902-8

Cited by 22 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pharmacotherapy of OAB relies essentially on the use of two β 3 -adrenergic agonists: vibegron ( Gemtesa ® , FDA-approved in 2020) and mirabegron ( Myrbetriq ® , FDA-approved in 2012) with a comparable limited efficacy, even if vibegron, with less side effect on blood pressure, is often preferred to mirabegron [ 5 , 6 , 7 , 8 ]. A few other options are available, including the use of botulinum toxin A, neuromodulation with implantable devices, and laser treatment but their efficacy is limited [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder

Sauzeau

Beignet²,

Bailly

2022

Biomedicines

View full text Add to dashboard Cite

Bladder pathologies, very common in the aged population, have a considerable negative impact on quality of life. Novel targets are needed to design drugs and combinations to treat diseases such as overactive bladder and bladder cancers. A promising new target is the ubiquitous Rho GTPase Rac1, frequently dysregulated and overexpressed in bladder pathologies. We have analyzed the roles of Rac1 in different bladder pathologies, including bacterial infections, diabetes-induced bladder dysfunctions and bladder cancers. The contribution of the Rac1 protein to tumorigenesis, tumor progression, epithelial-mesenchymal transition of bladder cancer cells and their metastasis has been analyzed. Small molecules selectively targeting Rac1 have been discovered or designed, and two of them—NSC23766 and EHT 1864—have revealed activities against bladder cancer. Their mode of interaction with Rac1, at the GTP binding site or the guanine nucleotide exchange factors (GEF) interaction site, is discussed. Our analysis underlines the possibility of targeting Rac1 with small molecules with the objective to combat bladder dysfunctions and to reduce lower urinary tract symptoms. Finally, the interest of a Rac1 inhibitor to treat advanced chemoresistance prostate cancer, while reducing the risk of associated bladder dysfunction, is discussed. There is hope for a better management of bladder pathologies via Rac1-targeted approaches.

show abstract

Section: Introductionmentioning

confidence: 99%

Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder

Sauzeau

Beignet²,

Bailly

2022

Biomedicines

View full text Add to dashboard Cite

show abstract

“…In the absence of head-to-head trials, Kennely et al performed an indirect treatment comparison of vibegron and mirabegron. 50 Vibegron was associated with significantly greater improvement from baseline in total incontinence episodes versus mirabegron at 4 and 52 weeks (p<0.05, each) and volume voided at 12 and 52 weeks (p<0.05, each). Incidence of AEs was generally comparable.…”

Section: Beta-3-agonistsmentioning

confidence: 86%

Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment

Gandi¹,

Sacco²

2021

CPAA

View full text Add to dashboard Cite

“…Data regarding the beta‐3 agonists are mixed. A systematic review found that overall, the efficacy of mirabegron and vibegron on micturition frequency and on urgency urinary incontinence episodes and continence was superior to placebo and comparable to anticholinergics 11 . Again the main distinction between mirabegron and anticholinergics was tolerability 10–12,14 .…”

Section: Oab Care As a Preference Sensitive Conditionmentioning

confidence: 99%

“…A systematic review found that overall, the efficacy of mirabegron and vibegron on micturition frequency and on urgency urinary incontinence episodes and continence was superior to placebo and comparable to anticholinergics. 11 Again the main distinction between mirabegron and anticholinergics was tolerability. [10][11][12]14 A network metaanalysis of 54 studies looking at 25 different drug formulations and doses, also found no significant differences in medical efficacy.…”

Section: Equipoise In Second-line Therapymentioning

confidence: 99%

Delivering patient‐centered care through shared decision making in overactive bladder

Paudel

Lane

2022

Neurourology and Urodynamics

View full text Add to dashboard Cite

Introduction Men and women living with overactive bladder (OAB) face many treatment decisions as they progress through the treatment pathway. Decisions to pursue specific therapies are highly preference sensitive and ideal for shared decision making (SDM). The aim of this narrative review is to provide urologists with a practical summary of methods to elicit preferences and facilitate SDM to promote patient‐centered care for OAB. Methods We explore OAB as a preference sensitive condition through a review of treatment outcomes and present available data on prediction tools, patient preferences, and decision aids. We propose a paradigm for applying Everyday SDM to OAB care. Results Clinical outcome data points to equipoise (balanced outcomes) between options for first‐, second‐, and third‐line OAB therapies, making OAB preference sensitive and appropriate for SDM. Methods to personalize care through individualized outcome prediction calculators and tools to elicit patient preferences are emerging. While patient information about OAB is readily available, we identified few OAB decision aids that facilitate patient preference elicitation and SDM. Conclusions OAB is a preference sensitive condition, where treatment is largely based on the patient's preferences and values. SDM is an ideal approach to supporting patients through these treatment decisions. We propose the application of Everyday SDM, a personalized, clinically efficient methodology as a method to support patient‐centered OAB care.

show abstract

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison

Cited by 22 publications

References 26 publications

Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder

Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder

Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment

Delivering patient‐centered care through shared decision making in overactive bladder

Contact Info

Product

Resources

About